Walgreens, Chicago Public Schools and the Chicago Department of Public Health are teaming up to help parents of students in grades 6 to 12 meet a new Illinois state requirement for Tdap vaccinations, which help to protect against whooping cough, the pharmacy operator announced.
According to a new report released by Express Scripts, the stress associated with providing unpaid care for a sick or disabled adult can create additional detrimental effects on the caregiver's health, leading to a 29% greater use of anti-anxiety medications compared with non-caregivers.
This year, generic drugs account for 83% of all drugs dispensed in the United States, and that figure is set to get even larger over the next few years. That was among the takeaways from IMS Health VP industry relations Doug Long’s presentation Sunday morning.
Meijer announced that it is expanding its mPerks digital coupon program to include pharmacy purchases, allowing customers to personalize their savings and earn rewards in the areas they shop the most whenever they fill a prescription.
Perrigo Co. announced that it has received final approval from the Food and Drug Administration for its abbreviated new drug applications for fluocinolone acetonide scalp oil, 0.01%, the generic equivalent to Derma-Smoothe/FS Scalp Oil, and fluocinolone acetonide topical oil, 0.01%, the generic equivalent to Derma-Smoothe/FS Body Oil.
Teva Pharmaceutical and Perrigo Co. announced the launch of the generic equivalent to Temodar (temozolomide). Teva will manufacture, market and distribute the product in the United States, and both companies will equally share in the cost and profitability of the product in the country.
VoicePort announced the launch of its Medication Synchronization automated solution with two U. S. pharmacy chain clients and are in final stage negotiations with several others in support of helping pharmacies deliver increased patient health-and-wellness.
Results of a recent federal survey of Medicare Part D claims is again roiling the sometimes strained relationship between independent and smaller-chain community pharmacies and managed care, and could herald a growing threat to those pharmacies as health plan payers and pharmacy benefit managers abandon open pharmacy provider networks and shift more business to exclusive preferred pharmacy groups.
Can one of the nation's premier specialty pharmacies maintain its focus on each patient it serves while simultaneously smashing its own growth records and reaching national power-player status in the rarified world of specialized medication services?
The Supreme Court usually has a lot on its plate in any given year, but this year's term included a pretty big case for the pharmaceutical industry: the Federal Trade Commission v. Actavis, which concerned legal settlements between branded and generic drug makers that often occur when the latter attempts to market a generic drug before the former's patents have expired.
The urgency behind Diplomat's launch of its Retail Specialty Network isn't hard to fathom. As the growth momentum in pharmaceuticals shifts from traditionally developed drugs to more complex and expensive specialty and biotech products, traditional pharmacies without access to these specialized medicines — and the patients who depend on them — find themselves stranded in a receding market like boats at low tide.